MDACC Study No:2005-0842 ( NCT No: NCT00501410)
Title:Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Metastatic Colorectal Cancer (CA180048)
Principal Investigator:Scott Kopetz
Treatment Agent:5-FU; Cetuximab; Dasatinib; Leucovorin; Oxaliplatin
Study Status:Closed
Study Description:The goal of the Phase I part of this clinical research study is to find the
highest tolerable dose of a combination of dasatinib, cetuximab, and FOLFOX
(5-fluorouracil [5-FU], leucovorin [LV], and Eloxatin [oxaliplatin]) that can
be given to patients with metastatic colorectal cancer. The safety of these
drugs in combination will also be studied.

The goal of the Phase II part of this clinical research study is to learn if
dasatinib given in combination with FOLFOX with or without cetuximab can help
to control metastatic colorectal cancer.
Hide details for General InformationGeneral Information

Disease Group:Colorectal
Phase of Study:Phase I
Treatment Agents:5-FU
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:This protocol will not require hospitalization for the patient.
Supported By:N/A
Return Visit:Patients will return to MDACC on a weekly basis to receive treatment
Home Care:Home care will not be required for this protocol

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Scott Kopetz
Dept:Gastrointestinal Medical Oncology
For Clinical Trial Enrollment:713-792-2828
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults